AIP
INZY

Ameritas Investment Partners’s Inozyme Pharma INZY Stock Holding History

Ameritas Investment Partners’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,805
Closed -$4.37K – 3266
2025
Q1 		$4.37K Hold
4,805
– – ﹤0.01% 2998
2024
Q4 		$13.3K Hold
4,805
– – ﹤0.01% 2814
2024
Q3 		$25.1K Hold
4,805
– – ﹤0.01% 2543
2024
Q2 		$21.4K Hold
4,805
– – ﹤0.01% 2581
2024
Q1 		$36.8K Hold
4,805
– – ﹤0.01% 2299
2023
Q4 		$20.5K Buy
4,805
+2,010
+72% +$7.14K ﹤0.01% 2574
2023
Q3 		$11.7K Hold
2,795
– – ﹤0.01% 2773
2023
Q2 		$15.6K Buy
+2,795
New +$16.5K ﹤0.01% 2695
2022
Q2 		– Sell
-692
Closed -$3K – 3150
2022
Q1 		$3K Hold
692
– – ﹤0.01% 3026
2021
Q4 		$5K Hold
692
– – ﹤0.01% 3039
2021
Q3 		$8K Hold
692
– – ﹤0.01% 2992
2021
Q2 		$12K Hold
692
– – ﹤0.01% 2902
2021
Q1 		$14K Hold
692
– – ﹤0.01% 2717
2020
Q4 		$14K Hold
692
– – ﹤0.01% 2648
2020
Q3 		$18K Buy
+692
New +$17.2K ﹤0.01% 2431

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Ameritas Investment Partners's INZY Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 4,805 shares — an estimated $4.37K sold.

Ameritas Investment Partners first reported a position in INZY in Q3 2020 and held it in 15 quarters. The position peaked at $36.8K in Q1 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Ameritas Investment Partners reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Ameritas Investment Partners sold 4,805 Inozyme Pharma shares in Q2 2025, an estimated $4.37K.
  • Ameritas Investment Partners first reported a position in Inozyme Pharma in Q3 2020 and held it in 15 quarters.
  • Ameritas Investment Partners's Inozyme Pharma position peaked at $36.8K in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.